SpringWorks Therapeutics Says Gomekli Receives FDA Approval for Genetic Disorder

MT Newswires Live02-12

SpringWorks Therapeutics (SWTX) said late Tuesday the US Food and Drug Administration has approved Gomekli, or mirdametinib, for the treatment of certain patients with neurofibromatosis type 1, a genetic disorder with symptoms including abnormal pigmentation and tumor growth.

The approval is based on findings from a phase 2b trial in which Gomekli showed a 41% objective response rate in adults and 52% in children, the company said.

SpringWorks received a rare pediatric disease priority review voucher and intends to make Gomekli available in the US within two weeks, it said.

The company also said it is seeking mirdametinib approval from the European Medicines Agency, with a decision expected this year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2510266913?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-02-12 17:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510266913","market":"fut","top_or_hot":-1,"title":"SpringWorks Therapeutics Says Gomekli Receives FDA Approval for Genetic Disorder","media":"MT Newswires Live","content":"<html><body><p> SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SWTX) said late Tuesday the US Food and Drug Administration has approved Gomekli, or mirdametinib, for the treatment of certain patients with neurofibromatosis type 1, a genetic disorder with symptoms including abnormal pigmentation and tumor growth.</p><p>The approval is based on findings from a phase 2b trial in which Gomekli showed a 41% objective response rate in adults and 52% in children, the company said.</p><p>SpringWorks received a rare pediatric disease priority review voucher and intends to make Gomekli available in the US within two weeks, it said.</p><p>The company also said it is seeking mirdametinib approval from the European Medicines Agency, with a decision expected this year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SpringWorks Therapeutics Says Gomekli Receives FDA Approval for Genetic Disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpringWorks Therapeutics Says Gomekli Receives FDA Approval for Genetic Disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-12 17:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SWTX) said late Tuesday the US Food and Drug Administration has approved Gomekli, or mirdametinib, for the treatment of certain patients with neurofibromatosis type 1, a genetic disorder with symptoms including abnormal pigmentation and tumor growth.</p><p>The approval is based on findings from a phase 2b trial in which Gomekli showed a 41% objective response rate in adults and 52% in children, the company said.</p><p>SpringWorks received a rare pediatric disease priority review voucher and intends to make Gomekli available in the US within two weeks, it said.</p><p>The company also said it is seeking mirdametinib approval from the European Medicines Agency, with a decision expected this year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510266913","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510266913","pubTimestamp":1739354205,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"SpringWorks Therapeutics  said late Tuesday the US Food and Drug Administration has approved Gomekli, or mirdametinib, for the treatment of certain patients with neurofibromatosis type 1, a genetic disorder with symptoms including abnormal pigmentation and tumor growth.The approval is based on findings from a phase 2b trial in which Gomekli showed a 41% objective response rate in adults and 52% in children, the company said.SpringWorks received a rare pediatric disease priority review voucher and intends to make Gomekli available in the US within two weeks, it said.The company also said it is seeking mirdametinib approval from the European Medicines Agency, with a decision expected this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4121":"生命科学工具和服务","SWTX":"SpringWorks Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"SpringWorks Therapeutics表示Gomekli获得FDA批准治疗遗传疾病","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GENE":1,"LENZ":1,"SWTX":0.9},"content_text":"SpringWorks Therapeutics (SWTX) said late Tuesday the US Food and Drug Administration has approved Gomekli, or mirdametinib, for the treatment of certain patients with neurofibromatosis type 1, a genetic disorder with symptoms including abnormal pigmentation and tumor growth.The approval is based on findings from a phase 2b trial in which Gomekli showed a 41% objective response rate in adults and 52% in children, the company said.SpringWorks received a rare pediatric disease priority review voucher and intends to make Gomekli available in the US within two weeks, it said.The company also said it is seeking mirdametinib approval from the European Medicines Agency, with a decision expected this year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.3","shortVersion":"4.32.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2510266913"}